Monoamine oxidase inhibitors in neurological diseases

Author(s)

• Lieberman, A. N. (Abraham N.)

Bibliographic Information

Monoamine oxidase inhibitors in neurological diseases

edited by Abraham Lieberman ... [et al.]

（Neurological disease and therapy, v. 21）

Marce Dekker, c1994

Note

Includes bibliographical references and index

Description and Table of Contents

Description

Emphasizing the role of monoamine oxidase (MAO) in the etiology and pathogenesis of Parkinson's disease and Alzheimer's disease, this up-to-date reference describes the genetics, physiology, biochemistry, pharmacology, and clinical aspects of this very important class of enzymes. Details how the interaction between selegiline (deprenyl) and MAO may retard the progression of neurodegenerative disorders! Providing the latest theories on how selegiline operates, Monoamine Oxidase Inhibitors in Neurological Diseases presents fundamental information on MAO types A and B examines the distribution of MAO A and B in the normal human brain investigates the effects of disease and aging on MAO A and B analyzes a critical role for MAO in the toxic action in Parkinson's disease elucidates selegiline's novel ability to delay the progression or repair the damage of dopaminergic neurons discusses the usefulness of MAO inhibitors in psychiatric disease and more!

Table of Contents

The Distribution of Monoamine Oxidases A and B in Normal Human Brain, Karin N. Westlund Effects of Disease and Aging on Monoamine Oxidases A and B, Manfred Gerlach, Peter Riederer, and Moussa B. H. Youdim Biochemistry and Mechanism of Action of Monoamine Oxidases A and B, Eimear M. O'Brien and Keith F. Tipton The Structure, Gene, and Promoter Organization of Monoamine Oxidases A and B, Jean Chen Shih, Kevin Chen, Joseph S. Grimsby, Qin-Shi Zhu, and Timothy K. Gallaher Molecular Genetics and Inheritance of Human Monoamine Oxidases A and B, Xandra O. Breakefield, Zheng-Yi Chen, Elizabeth Tivol, Christo Shalish, and Ian W. Craig Role of Monoamine Oxidase Genetics in the Etiology of Parkinson's Disease, Janice H. Kurth and Matthias C. Kurth Multiple Forms of Monoamine Oxidase and Iron: Their Relevance to the Pathology and Treatment of Parkinson's Disease, Moussa B. H. Youdim, Dorit Ben-Shachar, and Peter Riederer A Critical Role for Monoamine Oxidase in Toxin Action in Parkinson's Disease, Peter Jenner Effects of Monoamine Oxidase B Inhibitors on Dopaminergic Function: Role of 2-Phenylethylamine and Aromatic L-Amino Acid Decarboxylase, Augusto V. Juorio, Xin-Min Li, I. A. Paterson, and Alan A. Boulton Inhibition of Monoamine Oxidase B and the Neuroprotective Effects of Selegiline, Kevin T. Finnegan Reduction of Nerve Cell Death by Deprenyl Without Monoamine Oxidase Inhibition, William G. Tatton, Nadine A. Seniuk, William Y. H. Ju, and Karen S. Ansari Monoamine Oxidase Inhibitors as Neuroprotective Therapy, Warren Olanow and Donald B. Calne Selegiline as Symptomatic Treatment for Parkinson's Disease, Abraham Lieberman Monoamine Oxidase Inhibitors in Alzheimer's Disease, Jody Corey-Bloom and Leon J. Thal Role of Monoamine Oxidase Inhibitors in Psychiatry, David J. Houlihan and Samuel Gershon

by "Nielsen BookData"

Details

• NCID: BA22385274
• ISBN:
  • 0824790820
• LCCN: 93030602
• Country Code: us
• Title Language Code: eng
• Text Language Code: eng
• Place of Publication: New York
• Pages/Volumes: xviii, 371 p.
• Classification:
  • LCC : RC365
  • NLM : W1 NE33LD v. 21 1994
  • NLM : WL 359 M751 1994
  • DC20 : 616.8
• Subject Headings:
  • LCSH : Monoamine oxidase -- Inhibitors -- Therapeutic use
  • LCSH : Nervous system -- Degeration -- Chemotherapy
  • LCSH : Monoamine oxidase
  • LCSH : Selegiline -- Therapeutic use
  • LCSH : Parkinsonism -- Chemotherapy
  • MESH : Monoamine Oxidase -- metabolism
  • MESH : Monoamine Oxidase Inhibitors -- therapeutic use
  • MESH : Parkinson Disease -- etiology
  • MESH : Parkinson Disease -- drug therapy
• Parent Bibliography ID:
  • BA07483868